All News

PMR2.jpg

Is PMR the Next Indication for Tocilizumab?

d MedPage Today

About half of patients with steroid-dependent polymyalgia rheumatica (PMR) were able to get off steroids altogether when they were started on tocilizumab (Actemra) infusions, which also improved disease control in most cases, a randomized phase III trial showed.

Read Article
antibody (Keep)

Clinical Profiles Seen with NXP-2 Antibodies

d Jack Cush, MD

A recent review of the myositis associated autoantibody NXP-2 profiles its clinical associations with dermatomyositis (DM), calcinosis, severe myositis and, in some reports, with cancer.

Read Article
yoga-1240391.jpg

Yoga Fails to Benefit Knee Osteoarthritis

d Jack Cush, MD

The Annals of Internal Medicine has published a study showing online yoga education and an unsupervised yoga program may improve physical function did not improve knee pain after 12 weeks and 24 weeks.

Read Article

NIH: 27 pts w/ ROSAH (retinal dystrophy, optic N. edema, splenomegaly, anhidrosis, headache) syndrome, due to dominant mutation ALPK1 - an autoinflammatory Dz w fevers, HA, Abnl CNS MRI, deforming arthritis, AA amyloidosis . https://t.co/Pyb3QNrPnB https://t.co/wxtwOGpKFr

Links:

Dr. John Cush RheumNow ( View Tweet)
Is there link between PsA & autoinflammatory Dz? Study of 120 #PsA pts found 31% w/ AID gene variants (AP1S3, PLCG2, NOD2, NLRP12, all monoallelic variants adn 1/2 genes assoc w/ autosomal dominant disorders. https://t.co/KaL7jheDZ6 https://t.co/09CSW2W3tn

Links:

Dr. John Cush RheumNow ( View Tweet)
Cohort Hip & Cohort Knee (CHECK) study of biomarkers (serum hs-CRP, sCOMP, sPINP sOC and urine uCTX-2) in1002 pts w/ hip or knee OA. Shows CRP, uCTX-2 & sPINP (OR 1.11-1.40) were assoc w/ nocturnal & walking pain, but not fatigue https://t.co/EOU6i24KLO https://t.co/VQWfeLR01x

Links:

Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine Dosing and SLE Flares JAMA cohort study examining HCQ dosing in patients with SLE suggests that HCQ doses of 5 mg/kg per day or less, was associated with a higher risk of lupus flares, including moderate or severe lupus flares. https://t.co/B5HqxWDqD3 https://t.co/4crIFBV9XP

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR's State-by-State Report Cards for Rheumatic Disease New report examines access, affordability, and activity and lifestyle factors in all 50 states and DC evaluating how easy it is to live with a rheumatic disease in your state. https://t.co/MmzG9oTfnq https://t.co/UhSM22PMf5

Links:

Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGISTS - How do you deal with skin Psoriasis (PSO) activity in your Psoriatic Arthritis Pts?

Dr. John Cush RheumNow ( View Tweet)

#ACR22 abstracts: 0220 Do you think social media can enhance your rheuma medical education, research or professional development? @anzypanzywanzy @anjmsantiago @PhRheumaJr @rheum4you @RHEUMarampa @RheumaRambolMD @doktora_ging #ACRambassador 📌https://t.co/SZB4p0WNu8

Links:

Lisa 🐳🐬 rheumarhyme ( View Tweet)

New CDC data on vaccination/boosters during BA.5 wave for deaths, age 50+ https://t.co/HGyjNwUveD Compared w/unvaccinated: —92% reduction of death for 4 shots —No difference in reduction between 3 and 2 shots (~82%) [that's a 12-fold ⬇️risk of death for 4 shots in July 2022] https://t.co/3JDjCLbEyh

Links:

Eric Topol EricTopol ( View Tweet)
IBD Ups Risk of Psoriatic Disease Findings of a new study suggest a causal effect between inflammatory bowel disease (IBD) and psoriasis (PSO) as well as psoriatic arthritis (PsA), but not vice versa. https://t.co/twam1BcG8I https://t.co/8PFObkNn4J

Links:

Dr. John Cush RheumNow ( View Tweet)
STAR-RA study - real world claims data shows tofacitinib doesnt increase malignancy risk. Study of 83,295 pts (10,504 TOFA). Risk of malignancy w/ TOFA not increased (HR 1.01) w/ RWE or RCT-duplicate cohort (HR 1.1; 95% CI 0.85, 1.62) https://t.co/GIIvs2cK3s

Links:

Dr. John Cush RheumNow ( View Tweet)

EMA has approved 86 biosimilar medicines since 2006 and has issued a harmonizing statement for EU countries that biosimilars are interchangeable with their reference medicine or with an equivalent biosimilar. https://t.co/ajsP1ulZTQ

Links:

Dr. John Cush RheumNow ( View Tweet)

RINOMAX Trial studied single dose of 500 mg rituximab IV in myasthenia gravis - 47 MG pts randomized to RTX or PBO, after 4 mos RTX response (71% vs 29%) superior to PBO. Further studies are needed https://t.co/XvAWRH8fUz

Links:

Dr. John Cush RheumNow ( View Tweet)

Deep Vein Thrombosis reviewed in current Annals of Internal Medicine - VTE is the 3rd most common CVD, seen in 5% of population. Half of VTE assoc w/ transient preventable risk factors. Direct oral anticoagulants are effective and safer https://t.co/6utxivuwf6

Links:

Dr. John Cush RheumNow ( View Tweet)

Propensity matched pairs (n=237 872) of perioperative pts - gabapentin users and nonusers shows perioperative gabapentin use had significantly more delirium (RR 1.28), antipsychotic Rx (1.17 ) & pneumonia (1.11) vs nonusers post surgery https://t.co/UAZs7Vqy6O

Links:

Dr. John Cush RheumNow ( View Tweet)

Colchicine vs cimetidine in PFAPA (Periodic fever, aphthous stomatitis, pharyngitis, adenitis) syndrome. 72 pts given COL vs CIM x 3 mos: # of febrile attacks was significantly decreased by both Rx (noninferior to each other) https://t.co/MO7IQ0e8gf

Links:

Dr. John Cush RheumNow ( View Tweet)

Metals & Hyperuricemia (HU) (20 studies, 63,283 participants): Increased HUA risk arsenic (OR 1.7), calcium (OR 1.76), cadmium (OR 1.19), & lead (OR 1.56), BUT lower w/ molybdenum (OR  0.8). No effect w/ Cu, Fe, Mg, Zn, Cd, Co, Al, Hg, Tl https://t.co/xmdBCCBuEk

Links:

Dr. John Cush RheumNow ( View Tweet)

Burden of OA (knee, hip, hand) for India (1990 - 2019): was 23.5 million in 1990; rose to 62.35 million 2019 (prevalence of 5313 per 100,000). Most common - Knee OA > hand OA > hip OA. The prevalence was higher in females than males. https://t.co/1yMzUulBqk

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×